Brighton Collaboration

The Brighton Collaboration is an international voluntary collaboration that aims to facilitate the development, evaluation, and dissemination of high-quality information about the safety of human vaccines.

The primary aim of the Brighton Collaboration is to develop globally accepted and implemented standardized case definitions of adverse events following immunizations.

Brighton Related Scientific Articles

Gidudu J, Kohl K, Halperin S, Jammer S, Heath P, Hennig R, Hoet B, Rothstein E, Schuind A, Varricchio F, Wikke W. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2008;26: 6800-6813.

Iskander J, Gidudu J, Arboleda N, Huang WT. Selected Major Issues in Vaccine Safety. Ann NestleM 2008;66:93-102.

For a complete list of the Brighton's publications More >>

Vaccine Analytic Unit (VAU)

The VAU is a collaborative vaccine safety research infrastructure between the Department of Defense (DoD) and CDC with input from the FDA. The VAU utilizes the DoD's Defense Medical Surveillance System (DMSS) database to conduct evaluations of AEFIs potentially associated with the current anthrax vaccine according to the published anthrax vaccine adsorbed (AVA) research agenda.

Recently, the focus of the VAU has been expanded beyond biodefense vaccines to assess whether specific AEFIs are associated with vaccines administered in the DoD population that have critical implications for civilian public health. The VAU is also active in building the infrastructure for conducting rapid safety assessment of vaccines used within the DoD.

VAU Related Scientific Articles

Payne DC, Franske LH, Stehr-Green PA. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed. Pharmacoepidemiology and Drug Safety. 2006; 16(1):46-54.